Cbl-b Antibody **Rabbit Polyclonal** Antigen Affinity Purified Protein ID NP 733762.2 Catalog No. A302-902A GenelD 868 Lot No. A302-902A-1 ABOBA APPLICATIONS IP. IHC SPECIES REACTIVITY Human PRESUMED REACTIVITY Based on 100% sequence identity, this antibody is predicted to react with Mouse and Rat AMOUNT 100 ul CONCENTRATION 1000 ua/ml STORAGE/SHELF LIFE $2 - 8^{\circ} C / 1$ year from date of receipt PHYSICAL STATE Liquid BUFFER Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09% Sodium Azide ISOTYPE IgG ORIGIN USA PRODUCTION Antibody was affinity purified using an epitope specific to Cbl-b immobilized on solid support. PROCEDURES The epitope recognized by A302-902A maps to a region between residue 450 and 500 of human Cas-Br-M (murine) Ecotropic Retroviral Transforming Sequence b using the numbering given in entry NP_733762.2 (GeneID 868). Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG. APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use. Western Blot Not recommended

Immunoprecipitation 2 – 5 µg/mg lysate

Immunohistochemistry 1:500 – 1:2,000. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.


 APPLICATION NOTES
Western blot of immunoprecipitates performed using Normal Pig Serum (Cat. No. S100–020), Goat anti-Rabbit Light Chain HRP Conjugate (Cat. No. A120–113P) and 4–8% SDS–PAGE (link to IP-western blot protocol in Additional Info section below).
IHC HUMAN CONTROLS
Breast Carcinoma, Ovarian Carcinoma

ADDITIONAL INFO https://www.bethyl.com/product/A302-902A Use the link above to view SDS, a current list of citations, and other product specific information. IP-western blot protocol: https://www.bethyl.com/content/protocol_IP_WB

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc. Eric McIntush, PhD | Chief Scientific Officer Date: June 21, 2019


Bethyl Laboratories, Inc. • 25043 West FM 1097 • Montgomery, TX 77356 • 800.338.9579 • 936.597.6111 • 866.597.6105 (FAX) • www.bethyl.com • technical@bethyl.com

For in vitro laboratory use only. Not for any clinical, therapeutic or diagnostic use in humans or animals. Not for human or animal consumption. This product may not be resold or modified for resale without the prior written approval of Bethyl Laboratories, Inc. The information provided in this data sheet is believed to be correct but does not purport to be all-inclusive and is intended to be used as a guide. Bethyl Laboratories, Inc. shall not be liable or responsible in any way for use of either this information or the material supplied. Disposal of hazardous material may be subject to federal, state or local laws or regulations.



Detection of human Cbl-b by western blot of

immunoprecipitates. *Samples:* Whole cell lysate (1 mg for IP, 20% of IP loaded) from HeLa cells. *Antibodies:* Affinity purified rabbit anti-Cbl-b antibody A302-902A used for IP at 3 μ g/mg lysate. Cbl-b was also immunoprecipitated by rabbit anti-Cbl-b antibody A302-903A, which recognizes a downstream epitope. For blotting immunoprecipitated Cbl-b, A302-903A was used at 1 μ g/ml. *Detection:* Chemiluminescence with an exposure time of 3 minutes.



Detection of human Cbl-b by immunohistochemistry. *Sample:* FFPE section of human ovarian carcinoma. *Antibody:* Affinity purified rabbit anti- Cbl-b (Cat. No. A302-902A Lot1) used at a dilution of 1:1,000 (1µg/ml). *Detection:* DAB